Completed PHASE3 INTERVENTIONAL 2-arm NCT00437307

Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse (HECTOR)

Topotecan Plus Carboplatin im Vergleich Zur Standardtherapie (Paclitaxel Plus Carboplatin Oder Gemcitabin Plus Carboplatin) in Der Therapie Von Patientinnen Mit Platin-sensitivem Rezidivierten Epithelialen Ovarialkarzinom, Peritonealkarzinom Oder Tubenkarzinom

Sponsor: North Eastern German Society of Gynaecological Oncology

Conditions Ovarian Cancer

Interventions Topotecan

Updated 6 times since 2017 Last updated: Sep 21, 2016 Started: Mar 31, 2007 Primary completion: Jul 31, 2013 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Ovarian Cancer and is currently completed. North Eastern German Society of Gynaecological Oncology leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

North Eastern German Society of Gynaecological Oncology

Data source: North Eastern German Society of Gynaecological Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany